Literature DB >> 3970957

Core modification of human low-density lipoprotein by artificial triacylglycerol emulsion.

E Granot, R J Deckelbaum, S Eisenberg, Y Oschry, G Bengtsson-Olivecrona.   

Abstract

To determine whether an apolipoprotein-free artificial triacylglycerol emulsion can substitute for VLDL in studying cholesterol ester-triacylglycerol exchange processes between triacylglycerol-rich lipoproteins and cholesterol ester-rich lipoproteins, we used Intralipid to modify human plasma LDL. Intralipid was incubated with LDL in the presence of lipoprotein-poor plasma (d greater than 1.21 g/ml) at 37 degrees C. Intralipid served as an acceptor for cholesterol ester and as a donor of triacylglycerol, modifying the low-density lipoproteins so that triacylglycerol became the major core lipid in the particle - the contribution of cholesterol ester to LDL mass decreased from 38% to 18%, while that of triacylglycerol increased from 4.9% to 26%. On lipolysis most added LDL triacylglycerol (59-72%) was hydrolyzed, resulting in a smaller particle than the "native' LDL particle with net loss of cholesterol ester. Incubation of LDL with the original Intralipid emulsion resulted in modified LDL with a high relative weight of phospholipid (27.7%). On removal of excess phospholipid from Intralipid and incubation of the resultant "washed' Intralipid with LDL, the relative weight of phospholipid in modified LDL decreased to 20%, which was similar to that observed after incubation of LDL with VLDL. We demonstrate that artificial triacylglycerol emulsion can indeed substitute for VLDL in neutral lipid exchange processes, and further confirm that transfer of core cholesterol ester and triacylglycerol occurs independently of the apolipoproteins present in triacylglycerol-rich lipoproteins and LDL.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3970957     DOI: 10.1016/0005-2760(85)90203-6

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  Evaluation of CETP activity in vivo under non-steady-state conditions: influence of anacetrapib on HDL-TG flux.

Authors:  David G McLaren; Stephen F Previs; Robert D Phair; Steven J Stout; Dan Xie; Ying Chen; Gino M Salituro; Suoyu S Xu; Jose M Castro-Perez; Gregory J Opiteck; Karen O Akinsanya; Michele A Cleary; Hayes M Dansky; Douglas G Johns; Thomas P Roddy
Journal:  J Lipid Res       Date:  2015-12-09       Impact factor: 5.922

2.  Incubation of lipid emulsions with plasma lipoproteins modifies the fluidity of each particle.

Authors:  N F Chanson; J F Lontie; Y A Carpentier; C Motta
Journal:  Lipids       Date:  2001-08       Impact factor: 1.880

3.  The effects of short term lipid infusion on plasma and hepatic bile lipids in humans.

Authors:  R Pakula; F M Konikoff; A M Moser; F Greif; A Tietz; T Gilat; M Rubin
Journal:  Gut       Date:  1999-09       Impact factor: 23.059

4.  Neutral lipid transfer protein does not regulate alpha-tocopherol transfer between human plasma lipoproteins.

Authors:  E Granot; I Tamir; R J Deckelbaum
Journal:  Lipids       Date:  1988-01       Impact factor: 1.880

5.  [Distribution and elimination of medium- and long-chain fatty acids of a fat emulsion in lipoproteins of severely injured patients following bolus injection].

Authors:  G Wolfram; M Adolph; J Eckart
Journal:  Z Ernahrungswiss       Date:  1989-06

6.  LDL binding to lipid emulsion particles: effects of incubation duration, temperature, and addition of plasma subfractions.

Authors:  Nathalie F Chanson; Jean-François Lontie; Annette Gulik; Jacqueline Férézou; Yvon A Carpentier
Journal:  Lipids       Date:  2002-06       Impact factor: 1.880

7.  Effect of hypertriglyceridemia on endotoxin responsiveness in humans.

Authors:  T van der Poll; C C Braxton; S M Coyle; M A Boermeester; J C Wang; P M Jansen; W J Montegut; S E Calvano; C E Hack; S F Lowry
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

8.  Effect of lipid infusion on bile composition and lithogenicity in patients without cholesterol gall stones.

Authors:  M Rubin; Z Halpern; G Charach; A Dvir; E Antebi; T Gilat; D Lichtenberg
Journal:  Gut       Date:  1992-10       Impact factor: 23.059

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.